NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Multicenter evaluation of a bilayer polymer blood collection tube for coagulation testing: effect on routine hemostasis test results and on plasma levels of coagulation activation markers.

Author(s): Toulon P, Aillaud MF, Arnoux D, Boissier E, Borg JY, Gourmel C

Publication: Blood Coagul Fibrinolysis, 2006, Vol. 17, Page 625-31

PubMed ID: 17102648 PubMed Review Paper? No

Purpose of Paper

The purpose of this paper was to determine the effects of tube type, anticoagulant concentration, post-centrifugation delays to analysis, and tube age on routine hemostasis assays and coagulation activation markers in plasma.

Conclusion of Paper

No clinically relevant differences were observed in prothrombin time (PT), factor V (FV), activated partial thromboplastin time (APTT), anti-activated factor X (anti-FXa) activity, prothrombin fragment 1+2 (F1+2), or thrombin-antithrombin complexes (TAT) between specimens collected in plastic Vacuette and siliconized glass Vacutainer tubes, between specimens with two different citrate concentrations, between specimens collected in Vacuette tubes at the beginning or end of their shelf life, or in specimens after 6 h post-centrifugation delay to analysis at room temperature.

Studies

  1. Study Purpose

    The purpose of this study was to determine the effects of tube type, anticoagulant concentration, post-centrifugation delays to analysis, and tube age on routine hemostasis assays and coagulation activation markers in plasma. Routine hemostasis assays were performed immediately but plasma was stored at -70 degrees C until analysis of coagulation activation markers. Analysis was completed in 5 different centers using their own analyzers and reagents.

    Summary of Findings:

    Collection of specimens in plastic Vacuette versus siliconized glass Vacutainer tubes, with 0.109 mol/L versus 0.129 mol/L citrate, in Vacuette tubes at the beginning or end of their shelf life, and 6 h post-centrifugation delays to analysis at room temperature did not result in clinically relevant differences in PT, FV, APTT, or anti-FXa activities. Statistically significant variations were seen for these analytes with the different collection and processing conditions that were also dependent on type of anticoagulant therapy. Levels of F1+2 and TAT in plasma were statistically significantly lower in specimens collected in plastic tubes than in glass tubes, but the difference was not clinically relevant.

    Biospecimens
    Preservative Types
    • None (Fresh)
    • Frozen
    Diagnoses:
    • Not specified
    Platform:
    AnalyteTechnology Platform
    Protein Hematology/ auto analyzer
    Morphology Hematology/ auto analyzer
    Protein ELISA
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Preaquisition Other drugs No anticoagulant drugs
    Oral anticoagulants
    Unfractionated heparin
    Low molecular weight heparin derivative
    Biospecimen Acquisition Anticoagulant Sodium citrate
    Multiple concentrations evaluated
    Biospecimen Preservation Type of fixation/preservation Frozen
    None (fresh)
    Storage Time at room temperature 0 h
    6 h
    Biospecimen Acquisition Type of collection container/solution Vacuette (plastic) 11 months from expiration
    Vacuette (plastic) 1 month from expiration
    Vacutainer (glass)

You Recently Viewed  

News and Announcements

  • Most Downloaded SOPs in 2024

  • New Articles on the GTEx Project are Now FREELY Available!

  • Just Published!

  • More...